



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

KAYFANDA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
Variation type IB /	This was an application for a variation	10/07/2025	N/A		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



EMA/VR/0000268240	following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to submit, for both Kayfanda and Bylvay, the consolidated version (version 7.0) of odevixibat's EU RMP combining all the approved changes from EU RMP versions 6.2 and 6.3.				
Variation type IA_IN / EMA/VR/0000269338	A. ADMINISTRATIVE CHANGES - A.1 Change in the name and/or address of the marketing authorisation holder - Accepted	07/05/2025		SmPC, Labelling and PL	
Variation type IB / EMA/VR/0000249036	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted B.II.f.1.b Extension of the shelf life of the	03/04/2025		SmPC	

	finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted				
--	---	--	--	--	--